Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?

J Neurosurg. 2014 Oct;121(4):818-26. doi: 10.3171/2014.6.JNS132535. Epub 2014 Aug 8.

Abstract

Objectives: Methylation of O(6)-methylguanine-DNA methyltransferase (MGMT) has been reported to be a good prognostic factor for patients with glioblastoma multiforme (GBM). To determine whether the absolute value of MGMT messenger RNA (mRNA) might be a prognostic factor and useful for predicting the therapeutic effectiveness of temozolomide, especially with regard to GBMs, the authors measured the absolute value of MGMT mRNA in gliomas by using real-time reverse-transcription polymerase chain reaction (RT-PCR).

Methods: MGMT mRNA was measured in 140 newly diagnosed gliomas by real-time RT-PCR using the Taq-Man probe. Among 73 GBMs, 45 had been initially treated with temozolomide and radiation.

Results: The mean MGMT mRNA value was significantly lower in oligodendroglial tumors than in other tumors. In the 73 GBMs, a significant prognostic factor for progression-free survival was fewer than 1000 copies/ μgRNA of MGMT mRNA (p = 0.0150). Of 45 patients with GBMs that had been treated with temozolomide and radiation, progression-free survival was significantly longer for those whose GMB had fewer than 1000 copies/μgRNA of MGMT mRNA than for those whose GBM had more than 1000 copies/μgRNA (p = 0.0090). In 32 patients with GBMs treated by temozolomide and radiation whose age was younger than 75 years and whose Karnofsky Performance Scale score was more than 70, progression-free and overall survival times were longer for those with GBMs of fewer than 5000 copies/μgRNA of MGMT mRNA than for those with GBMs of more than 5000 copies/μgRNA (p = 0.0365 and p = 0.0312).

Conclusions: MGMT mRNA might be useful as a prognostic factor and for predicting the results of therapy for GBMs treated by temozolomide. New individual adjuvant therapy based on the results of MGMT mRNA quantitation has been proposed.

Keywords: ACNU = 1-(4-amino-2-methyl-5-pyrimidynyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride; G-CIMP = glioma-CpG island methylator phenotype; GADPH = glyceraldehyde-3-phosphate dehydrogenase; GBM = glioblastoma multiforme; MGMT; MGMT = O6-methylguanine-DNA methyltransferase; RT-PCR = reverse-transcription polymerase chain reaction; cDNA = complementary DNA; glioblastoma; mRNA; mRNA = messenger RNA; oncology; real-time RT-PCR; temozolomide.

MeSH terms

  • Adult
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Brain Neoplasms / chemistry
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / genetics*
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Disease-Free Survival
  • Female
  • Glioblastoma / chemistry
  • Glioblastoma / drug therapy*
  • Glioblastoma / genetics*
  • Humans
  • Male
  • Middle Aged
  • O(6)-Methylguanine-DNA Methyltransferase / genetics*
  • Prognosis
  • RNA, Messenger* / analysis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Temozolomide

Substances

  • Antineoplastic Agents, Alkylating
  • RNA, Messenger
  • Dacarbazine
  • O(6)-Methylguanine-DNA Methyltransferase
  • Temozolomide